Trial data has shown recently-approved Epclusa (sofosbuvir+velpatasvir) gives cure rates of 89% of above, and can be used without interferon, and in most cases without ribavirin – reducing side ...

The FDA approved Vosevi (sofosbuvir+velpatasvir+voxilepravir), offering a single-tablet regimen for retreatment of adults with any of the six major hepatitis C genotypes who have previously ...

and/or sofosbuvir, but no prior treatment with an HCV NS3/4A protease inhibitor or NS5A inhibitor; (genotype 3): treat for 16 weeks if previously treated with regimens containing PEG-IFN ...